Studies of the effects of FK506 on renal allografting in the beagle dog

Takenori Ochiai, M. Nagata, K. Nakajima, T. Suzuki, K. Sakamoto, K. Enomoto, Y. Gunji, T. Uematsu, Takesada Goto, S. Hori, T. Kenmochi, T. Nakagouri, T. Asano, K. Isono, K. Hamaguchi, H. Tsuchida, K. Nakahara, N. Inamura, Toshio Goto

Research output: Contribution to journalArticlepeer-review

134 Citations (Scopus)


The immunosuppressive activities of a newly discovered macrolide extracted from Streptomyces tsukubaen-sis, FK506, were examined using 38 renal allografts in the beagle dog. The median survival time was 15.5 days in dogs without treatment, 61 days with a dose of 0.08 mg/kg/day and 176 days with a dose of 0.16 mg/kg/day of intramuscularly administered FK506. Prolongation of survival was statistically significant when compared with controls (P = 0.02, 0.0044, respectively). None of 6 recipient dogs receiving the agent at a dose of 0.16 mg/kg/day encountered rejection during the treatment course. Three of them survived over 200 days. Oral administration of FK506 at a dose of 0.32 mg/kg/day did not prolong the median survival time (20.5 days) compared with the placebo treated control (16.5 days), but oral treatment with 1.0 mg/kg/day resulted in all of the recipient dogs surviving over 130 days. Histological studies of 7 kidney graft biopsy specimens of the dogs surviving over 3 months revealed no cell infiltration or only some degree of reversible interstitial cell infiltration, but vascular and glomerular changes were not observed in any of the specimens. Irregularity of nuclear shape and cytoplasmic vacuolation of the pars recta of the proximal tubules were observed in one dog each. Liver biopsy specimens showed no consistent evidence of hepatocellular damage. Three dogs died of intussusception 2–3 weeks posttransplant. The dogs treated intramuscularly with 0.32 mg/kg/day suffered from anorexia. Two dogs receiving oral treatment at a dose of 1.0 mg/kg developed papilloma of the skin around day 60, but the tumors disappeared by day 120. We conclude that FK506 is a powerful immunosuppressant in the dog with tolerable side effects.

Original languageEnglish
Pages (from-to)729-733
Number of pages5
Issue number6
Publication statusPublished - 12-1987
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Transplantation


Dive into the research topics of 'Studies of the effects of FK506 on renal allografting in the beagle dog'. Together they form a unique fingerprint.

Cite this